Recruiting

Vitamin B6 with Levetiracetam

Sponsor:

Duke University

Code:

NCT07271966

Conditions

Brain Tumor Related Epilepsy (BTRE)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vitamin B6 100 MG

Study Details

Brief summary:

This is a supportive care study to assess the effect of Vitamin B6 supplementation on mood-related side effects of levetiracetam in patients with brain tumors, who have already been prescribed levetiracetam for the prevention of seizures. This study will assess this effect from the perspective of both the patient and the patient's caregiver.

Patients will receive Vitamin B6 as a supplement to take daily for 8 to 12 weeks, in addition to the already prescribed levetiracetam and will undergo study assessments as well as complete self-reported questionnaires to evaluate their mood during the course of the study. Additionally, each patient will be asked to optionally identify a designated caregiver, who will complete questionnaires assessing the patient's mood changes, at the same time interval as the patient.

Conditions

Brain Tumor Related Epilepsy (BTRE)

Study ID

NCT07271966

Start date

May 29, 2026

Status verified date

Nov, 2025

Completion date

May 31, 2028

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria for Patients:

1. Age ≥ 18 years
2. Diagnosed with a primary brain tumor
3. Karnofsky Performance Status ≥ 70%
4. Have one or more documented seizures or transient events concerning for localization-related epilepsy requiring anti-seizure medication prophylaxis
5. Have an active immediate release levetiracetam prescription
6. Taking levetiracetam for ≥ 6 weeks and ≤ 6 months before screening
7. Baseline patient-reported mood symptoms and/or National Comprehensive Cancer Network distress thermometer score ≥ 3
8. Has access to e-mail where they can receive electronic informed consent form (ICF) and questionnaires
9. Signed ICF approved by the institutional review board (IRB)

Inclusion Criteria for Caregivers:

1. Age ≥ 18 years
2. Patient has indicated that it is acceptable to recruit their caregivers into the study
3. Able to read and write English
4. Has access to e-mail where they can receive electronic ICF and questionnaires
5. Signed ICF approved by the IRB

Exclusion Criteria for Patients:

1. Active prescription for steroids at the time of enrollment
2. Prescription for extended-release levetiracetam
3. Previous history of suicidal ideation, homicidal ideation, hallucinations, psychosis, depression leading to hospitalization, or mood disturbance leading to hospitalization
4. Prior history of alcohol use disorder or substance use disorder
5. Refractory epilepsy requiring second or third line anti-seizure medication in addition to levetiracetam at the time of enrollment
6. Patients who are currently pregnant or breastfeeding/chestfeeding
7. Patients with a pre-existing history of neuropathy
8. Known history of Vitamin B6 toxicity or deficiency
9. Prior history of gastric surgery or colectomy
10. Prior history of autoimmune disease, such as Crohn's, Ulcerative Colitis, or Celiac disease
11. Prescribed Theophylline (Aquaphyllin, Elixophyllin, Theolair, Truxophyllin) used in the treatment of asthma, chronic bronchitis, and emphysema
12. Cognitive impairment that affects the patient's ability to comprehend and provide responses to questionnaires

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Vitamin B6 supplementation

Interventions

Vitamin B6 100 MG

Patients will be prescribed 100 mg of Vitamin B6 as a supplement to take daily in the morning, by mouth for 8 to 12 weeks, in addition to the already prescribed levetiracetam.

Primary outcome measure

  • Efficacy of VitB6 supplementation on LEV-associated mood changes in patients with BTRE, as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) anger questionnaire [ Time Frame: From enrollment (Baseline) to follow-up at 8-12 weeks from the initiation of VitB6 supplementation ]

Central Contacts and Locations

Central contacts

Katherine Peters, MD, PhD

919-684-5301dukebrain1@duke.edu

Locations

Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 27710

More Information

Sponsor

Duke University

Last update posted

Jul 29, 2026

Last verified

Nov, 2025

Keywords

  • BTRE
  • Vitamin B6
  • Levetiracetam
  • Katherine Peters
  • Pro00119210
  • Brain tumor

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Duke University on 2026-07-29.